Waverley Pharma Inc (WAVE) - Total Liabilities
Based on the latest financial reports, Waverley Pharma Inc (WAVE) has total liabilities worth CA$3.64 Million CAD (≈ $2.63 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Waverley Pharma Inc (WAVE) cash flow conversion to assess how effectively this company generates cash.
Waverley Pharma Inc - Total Liabilities Trend (2015–2024)
This chart illustrates how Waverley Pharma Inc's total liabilities have evolved over time, based on quarterly financial data. See WAVE net asset value for net asset value and shareholders' equity analysis.
Waverley Pharma Inc Competitors by Total Liabilities
The table below lists competitors of Waverley Pharma Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
CABASSE S.A. EO -50
F:LB0
|
Germany | €10.20 Million |
|
CT UK High Income Trust Plc
LSE:CHIB
|
UK | GBX18.35 Million |
|
Anexo Group Plc
LSE:ANX
|
UK | GBX115.42 Million |
|
HODL SPAC EUROPE AB
F:NW1
|
Germany | €6.13 Million |
|
GRIT Real Estate Income Group
LSE:GR1T
|
UK | GBX738.44 Million |
|
ONETECH SOLUTIONS HOLDINGS BERHAD
KLSE:03041
|
Malaysia | RM3.90 Million |
|
Cadence Minerals PLC
LSE:KDNC
|
UK | GBX1.23 Million |
|
Multistack International Ltd
AU:MSI
|
Australia | AU$2.90 Million |
Liability Composition Analysis (2015–2024)
This chart breaks down Waverley Pharma Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see WAVE market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.11 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.54 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 2.85 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Waverley Pharma Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Waverley Pharma Inc (2015–2024)
The table below shows the annual total liabilities of Waverley Pharma Inc from 2015 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CA$4.08 Million ≈ $2.95 Million |
+95.18% |
| 2023-12-31 | CA$2.09 Million ≈ $1.51 Million |
+30.87% |
| 2022-12-31 | CA$1.60 Million ≈ $1.15 Million |
-15.76% |
| 2021-12-31 | CA$1.89 Million ≈ $1.37 Million |
+30.77% |
| 2020-12-31 | CA$1.45 Million ≈ $1.05 Million |
-6.42% |
| 2019-12-31 | CA$1.55 Million ≈ $1.12 Million |
+22.48% |
| 2018-12-31 | CA$1.26 Million ≈ $914.54K |
-21.04% |
| 2017-12-31 | CA$1.60 Million ≈ $1.16 Million |
+13556.93% |
| 2016-12-31 | CA$11.72K ≈ $8.48K |
+10.13% |
| 2015-12-31 | CA$10.65K ≈ $7.70K |
-- |
About Waverley Pharma Inc
Waverley Pharma Inc., a biopharmaceutical company, researches, develops, and commercializes oncology therapeutics in the United Kingdom. The company develops poly ADP-ribose polymerase-1 (PARP-1) inhibitors for cancer treatment. It also operates a retail pharmacy in the United States. Waverley Pharma Inc. was founded in 2014 and is headquartered in Winnipeg, Canada.